Core Insights - LifeMD, Inc. has appointed Atul Kavthekar as Chief Financial Officer to support its growth phase, with Marc Benathen departing to pursue new opportunities [1][2][6] Leadership Changes - Atul Kavthekar brings nearly three decades of experience in healthcare and technology, focusing on financial infrastructure and operational performance [2][3] - Chris Pisano has been appointed as Chief Marketing Officer, bringing over 25 years of marketing experience to enhance brand strategy and market positioning [4][6] - Jessica Friedeman will assume the role of Chief Business Officer, focusing on enterprise and employer health offerings while continuing her leadership in women's health [5][6] Strategic Focus - Kavthekar will work with the technology team to position LifeMD as an AI-first healthcare company, aiming to improve patient access and clinical outcomes [3][4] - The leadership changes are designed to leverage the strengths of the management team as LifeMD enters a new growth phase [6] Employment Inducement Grant - As part of his employment, Kavthekar will receive 675,000 restricted stock units, with vesting conditions based on service and performance targets [7] Company Overview - LifeMD is a leading provider of virtual primary care services, offering telemedicine and specialized treatment across over 200 conditions [8]

Core Insights - LifeMD, Inc. reported strong financial results for Q1 2025, achieving its first-ever quarter of GAAP profitability ahead of expectations [3][5] - The company experienced significant growth in telehealth services, with a 70% year-over-year increase in telehealth revenue [5][8] - LifeMD raised its full-year 2025 guidance for total revenues and adjusted EBITDA, reflecting robust performance in the telehealth segment [5][14] Financial Performance - Total revenues increased by 49% year-over-year to $65.7 million, with telehealth revenue contributing $52.5 million [8][9] - Adjusted EBITDA rose to $8.7 million from $0.1 million in the same period last year [9][30] - GAAP net income was reported at $0.6 million, or $0.01 per diluted share, compared to a net loss of $7.5 million, or ($0.19) per share, in Q1 2024 [9][21] Subscriber Growth - Telehealth active subscribers increased by 22% to approximately 290,000 [9][10] - Total active subscribers across all services reached 448,925, marking an 11% increase year-over-year [10] Strategic Initiatives - LifeMD expanded its service offerings, including the launch of men's hormone therapy and acceptance of Medicare, which are expected to enhance its telehealth platform [3][4] - The company formed strategic collaborations with LillyDirect and NovoCare to provide access to branded GLP-1 medications, positioning itself as a unique telehealth provider in the U.S. [4] Financial Guidance - For the full year 2025, LifeMD expects total revenues in the range of $268 million to $275 million, up from previous guidance of $265 million to $275 million [5][14] - Adjusted EBITDA guidance was raised to a range of $31 million to $33 million, reflecting strong year-to-date performance [5][14]